The Kidney in Plasma Cell DyscrasiasAvailable to Purchase
In recent years, the knowledge of how renal damage occurs in patients with plasma cell dyscrasias / myeloma has substantially increased. For the first time, this publication brings together issues relating to the diagnosis and pathogenesis of these disorders, as well as a summary of advances achieved in the treatment and management of patients. Several chapters are devoted to various glomerulopathies associated with deposition of immunoglobulin light and heavy chains, including those associated with amyloidosis. The sequential events are pointed out, crucial steps and key molecules open to modulation or control are delineated, and therapeutic advances are highlighted. Although the emphasis is on the management of cases with renal involvement, a distinct focus on the diseases as a whole and their impact on patients’ general health and prognosis has been maintained throughout the discussions. Using a translational approach to renal manifestations in patients with plasma cell dyscrasias / myelomas, this publication conveys a comprehensive state-of-the-art view of the subject. It is aimed at practicing renal pathologists, nephrologists, internists and hematologists, as well as at trainees and scientists working in these specialties.
Download citation file:
Digital Version
Print Version
Table of Contents
-
1 - 4: The Kidney in Plasma Cell Dyscrasias: A Current View and a Look at the FutureByGuillermo A. HerreraGuillermo A. HerreraDepartment of Pathology, Saint Louis University School of Medicine,Saint Louis, Mo., USASearch for other works by this author on:
-
5 - 24: A History of the Kidney in Plasma Cell DisordersByDavid P. Steensma;David P. SteensmaMayo Clinic, Rochester, Minn., USASearch for other works by this author on:Robert A. KyleRobert A. KyleMayo Clinic, Rochester, Minn., USASearch for other works by this author on:
-
25 - 43: Pathologic Studies Useful for the Diagnosis and Monitoring of Plasma Cell DyscrasiasByDiana M. Veillon;Diana M. VeillonDepartment of Pathology, Louisiana State University, Health Sciences Center, Shreveport, La., USASearch for other works by this author on:James D. CotelingamJames D. CotelingamDepartment of Pathology, Louisiana State University, Health Sciences Center, Shreveport, La., USASearch for other works by this author on:
-
44 - 65: Serum Free Light Chains in the Diagnosis and Monitoring of Patients with Plasma Cell DyscrasiasByMary M. Mayo;Mary M. MayoDepartment of Pathology, Saint Louis University, St. Louis, Mo., USASearch for other works by this author on:Gretchen Schaef JohnsGretchen Schaef JohnsDepartment of Pathology, Saint Louis University, St. Louis, Mo., USASearch for other works by this author on:
-
66 - 86: Mechanisms of Renal Damage in Plasma Cell Dyscrasias: An OverviewByGiampaolo Merlini;Giampaolo MerliniaAmyloidosis Center, Biotechnology Research Laboratories, Fondazione, IRCCS Policlinico San Matteo and Department of Biochemistry, University of Pavia, Pavia,Search for other works by this author on:Claudio PozziClaudio PozzibDepartment of Nephrology and Dialysis, A. Manzoni Hospital, Lecco, ItalySearch for other works by this author on:
-
87 - 104: Proximal Tubular Injury in MyelomaByVecihi BatumanVecihi BatumanTulane University Medical Center, Section of Nephrology-Hypertension,New Orleans, La., USASearch for other works by this author on:
-
105 - 115: Paraproteinemic Renal Diseases that Involve the Tubulo-InterstitiumByGuillermo A. Herrera;Guillermo A. HerreraaDepartment of Pathology, St. Louis University, St. Louis, Mo.,Search for other works by this author on:Paul W. SandersPaul W. SandersbDivision of Nephrology, Department of Medicine,cDepartment of Physiology and Biophysics,University of Alabama at Birmingham, Birmingham, Ala.,dDepartment of Veterans Affairs Medical Center, Birmingham, Ala., USASearch for other works by this author on:
-
116 - 134: The Mesangium as a Target for Glomerulopathic Light and Heavy Chains: Pathogenic Considerations in Light and Heavy Chain-Mediated Glomerular DamageByJohn Keeling;John KeelingDepartment of Pathology, Saint Louis University School of Medicine,St. Louis, Mo., USASearch for other works by this author on:Guillermo A. HerreraGuillermo A. HerreraDepartment of Pathology, Saint Louis University School of Medicine,St. Louis, Mo., USASearch for other works by this author on:
-
135 - 155: Immunoglobulin Light and Heavy Chain Amyloidosis AL/AH: Renal Pathology and Differential DiagnosisByMaria M. PickenMaria M. PickenLoyola University Chicago, Loyola University Medical Center, Department of Pathology, Maywood, Ill., USASearch for other works by this author on:
-
156 - 181: Diversity and Diversification of Light Chains in Myeloma:The Specter of Amyloidogenesis by ProxyByMinyi Gu;Minyi GuBiosciences Division, Argonne National Laboratory, Argonne, Ill., USASearch for other works by this author on:Rosemary Wilton;Rosemary WiltonBiosciences Division, Argonne National Laboratory, Argonne, Ill., USASearch for other works by this author on:Fred J. StevensFred J. StevensBiosciences Division, Argonne National Laboratory, Argonne, Ill., USASearch for other works by this author on:
-
182 - 194: High-Dose Therapy in Patients with Plasma Cell Dyscrasias and Renal DysfunctionByMauricio Pineda-Roman;Mauricio Pineda-RomanMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Ark., USASearch for other works by this author on:Guido TricotGuido TricotMyeloma Institute for Research and Therapy, University of Arkansas for Medical Sciences, Little Rock, Ark., USASearch for other works by this author on:
-
195 - 210: Current and Emerging Views and Treatments of Systemic Immunoglobulin Light-Chain (AL) AmyloidosisByRaymond L. ComenzoRaymond L. ComenzoCytotherapy Laboratory, Memorial Sloan-Kettering Cancer Center,New York, N.Y., USASearch for other works by this author on: